Ritonavir and Suzetrigine interaction

Ritonavir and Suzetrigine: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Ritonavir (Norvir) label · effective 2026-07-23

Major

…Inhibitors: lovastatin, simvastatin ○ Microsomal triglyceride transfer protein (MTTP) Inhibitor: lomitapide ○ Non-opioid Analgesic (selective blocker of Na v 1.8 sodium channels): suzetrigine ○ PDE5 Inhibitor: sildenafil (Revatio ® ) when used for the treatment of pulmonary arterial hypertension ○ Sedative/Hypnotics: triazolam, orally administered midazolam •…

Contraindicationsnames SuzetrigineView label on DailyMed
Major

Analgesics, Non-opioid (selective blocker of Na v 1.8 sodium channels) suzetrigine ↑ suzetrigine and active metabolite M6-SUZ Co-administration contraindicated due to potential for serious and/or life-threatening suzetrigine adverse reactions [see Contraindications ( 4 ) ] .

Drug interactionsnames SuzetrigineView label on DailyMed

From the Suzetrigine (JOURNAVX) label · effective 2026-04-13

Major

Concomitant use of JOURNAVX with strong CYP3A inhibitors is contraindicated [see Warnings and Precautions (5.1) , Drug Interactions (7.1) ] .

Contraindicationsby drug classView label on DailyMed
Major

Concomitant use with strong CYP3A inhibitors is contraindicated.

Contraindicationsby drug classView label on DailyMed
Major

Concomitant use of JOURNAVX with strong CYP3A inhibitors is contraindicated [see Drug Interactions (7.1) , Clinical Pharmacology (12.3) ] .

Warnings and precautionsby drug classView label on DailyMed
Major

Strong and Moderate CYP3A inhibitors : Concomitant use with strong CYP3A inhibitors is contraindicated.

Drug interactionsby drug classView label on DailyMed
Moderate

Increased Risk of Adverse Reactions with Concomitant Use with Strong or Moderate CYP3A Inhibitors Strong and moderate CYP3A inhibitors increase suzetrigine and M6-SUZ (active metabolite) exposures which may cause JOURNAVX adverse reactions.

Warnings and precautionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.